Adverse drug reactions: Back to the future

British Journal of Clinical Pharmacology

Volumn 55, Issue 5, 2003, Pages 486-492

  Pirmohamed, Munir ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMFEBUTAMONE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; AZAPROPAZONE; CARBAMAZEPINE; CELECOXIB; CLOZAPINE; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; IBUPROFEN; METHOTREXATE; METIPRANOLOL; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PANCREATIN; PERGOLIDE; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; REMOXIPRIDE; RIFABUTIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROFECOXIB; TACROLIMUS; TETRACAINE; UNINDEXED DRUG; VIGABATRIN; WARFARIN;

APLASTIC ANEMIA; BLOOD TOXICITY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COLON DISEASE; CONFERENCE PAPER; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS DISEASE; FIBROSIS; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE OBSTRUCTION; LIPODYSTROPHY; NEPHROTOXICITY; PEPTIC ULCER; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; THROMBOEMBOLISM; UNITED KINGDOM; UVEITIS; VISUAL FIELD DEFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; DRUG HYPERSENSITIVITY; DRUG TOXICITY; FORECASTING; HEMORRHAGE; HUMANS; PHARMACEUTICAL PREPARATIONS; WARFARIN;

EID: 0037716386     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01847.x     Document Type: Conference Paper

References (64)

1. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. Br Med J 1998; 316: 1295-1298.
2. Routledge P. 150 years of pharmacovigilance. Lancet 1998; 351: 1200-1201.
3. Pirmohamed M, Kitteringham NR, Park BK. The role of active metabolites in drug toxicity. Drug Saf 1994; 11: 114-144.
4. Hallas J, Harvald B, Gram LF, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990; 228: 83-90.
5. Jefferys DB, Leakey D, Lewis JA, Payne S, Rawlins MD. New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol 1998; 45: 151-156.
6. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215-2220.
7. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients - A meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205.
8. Kvasz M, Allen IE, Gordon MJ, et al. Adverse drug reactions in hospitalized patients: a critique of a meta-analysis. Medgenmed 2000; 6: E3.
9. Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients. A systematic review of the prospective and retrospective studies. Bandolier Extra 2002; 1-16.
10. Green CF, Mottram DR, Rowe PH, Pirmohamed M. Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study. J Clin Pharm Ther 2000; 25: 355-361.
11. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? J Roy Coll Phys London 1995; 29: 41-49.
12. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 1999; 281: 1728-1734.
13. Lee A, Bateman DN, Edwards C, Smith JM, Rawlins MD. Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. Br Med J 1997; 315: 519.
14. Morrison-Griffiths S, Pirmohamed M, Walley T. Reporting of adverse drug reactions: practice in the UK. Nursing Times 1998; 94: 52-54.
15. Love L, Couig MP. The MedWatch Program. J Toxicol Clin Toxicol 1999; 37: 803-807.
16. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350: 1097-1099.
17. Evans JM, McNaughton D, Donnan PT, MacDonald TM. Pharmacoepidemiological research at the Medicines Monitoring Unit, Scotland: data protection and confidentiality. Pharmacoepidemiol Drug Saf 2001; 10: 669-673.
18. Davies DM, Ferner RE, de Glanville H. Davies's Textbook of Adverse Drug Reactions, 5th edn. London: Chapman & Hall Medical, 1998.
19. John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001; 6: 9-20.
20. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002; 16: 2013-2018.
21. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-580.
22. Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet 2002; 359: 040-541.
23. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995; 141: 539-545.
24. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998; 104 (3A): 23S-29S; discussion 41S-42S.
25. Blower AL, Brooks A, Fenn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11: 283-291.
26. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of tare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000; 85 (1-2): 169-182.
27. Garcia Rodriguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104 (3A): 30S-34S; discussion 41S-42S.
28. Chan FK, Leung WK. Peptic-ulcer disease. Lancet 2002; 360: 933-941.
29. Yeomans ND, Cook GA, Giraud AS. Selective COX-2 inhibitors: Are they safe for the stomach? Gastroenterology 1998; 115: 227-229.
30. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOK Study Group. N Engl J Med 2000; 343: 1520-1528.
31. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
32. Wiholm BE. Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database. Curr Med Res Olin 2001; 17: 210-216.
33. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002; 25: 537-544.
34. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-I variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 13926-13931.
35. Lip GY, Hart RG, Conway DS. Antithrombotic therapy for atrial fibrillation. Br Med J 2002; 325: 1022-1025.
36. Evans JM, Henderson LE, Goudie B, MacDonald TM, Davey PG. Demand for warfarin anticoagulation monitoring in Tayside. Scotland Health Bull (Edinburgh) 1997; 55: 88-93.
37. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996; 124: 970-979.
38. Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. Br Med J 2002; 325: 1073-1075.
39. Kettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39-42.
40. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-719.
41. Pirmohamed M, Park BK. Pharmacogenetics of adverse drug reactions. In Horizons in Medicine 14. ed. Neuberger J. London: Royal College of Physicians, 2003; in press.
42. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22: 298-305.
43. Park BK, Pirmohamed M, Kitteringham NR. The role of drug disposition in drug hypersensitivity: a chemical, molecular and clinical perspective. Chem Res Toxicol 1998; 11: 969-988.
44. Carstairs KC, Breckenridge A, Dollery CT, Worlledge SM. Incidence of a positive direct Coombs test in patients on alpha- methyldopa. Lancet 1966; 2: 133-135.
45. Breckenridge A, Dollery CT, Worlledge SM, Holborow EJ, Johnson GD. Positive direct Coombs tests and antinuclear factor in patients treated with methyldopa. Lancet 1967; ii: 1265-1267.
46. Carstairs K, Worlledge S, Dollery CT, Breckenridge A. Methyldopa and haemolytic anaemia. Lancet 1966; i: 201.
47. Murphy WG, Kelton JG. Methyldopa-induced autoantibodies against red blood cells. Blood Rev 1988; 2: 36-42.
48. Breckenridge A. A clinical pharmacologist's view of drug toxicity. Br J Clin Pharmacol 1996; 42: 53-58.
49. Breckenridge A. Science medicine and clinical pharmacology. The Lilly Lecture 1994. Br J Clin Pharmacol 1995; 40: 1-9.
50. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155: 2285-2290.
51. Pearce RE, Vakkalagadda GR, Leeder JS. Pathways of carbamazepine bioactivation in vitro 1. Characterization of human cytochromes P450 responsible for the formation of 2-and 3-hydroxylated metabolites. Drug Metab Dispos 2002; 30: 1170-1179.
52. Pirmohamed M, Alott A, Green VJ, Kitteringham NR, Chadwick D, Park BK. Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy. Br J Clin Pharmacol 1994; 37: 577-581.
53. Madden S, Maggs JL, Park BK. Bioactivation of carbamazepine in the rat in vivo - evidence for the formation of reactive arene oxide(s). Drug Metab Dispos 1996; 24: 469-479.
54. Lillibridge JH, Amore BM, Slattery JT, et al. Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab Dispos 1996; 24: 509-514.
55. Gaedigk A, Spielberg SP, Grant DM. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994; 4: 142-153.
56. Green VJ, Pirmohamed M, Kitteringham NK, et al. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol 1995; 50: 1353-1359.
57. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 1998; 39(Suppl 7): S8-S16.
58. Park BK, Pirmohamed M, Kitteringham NK. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34: 377-395.
59. Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 2001; 56: 890-896.
60. Pichler WJ, Yawalkar N. Allergic reactions to drugs: involvement of T cells. Thorax 2000; 55(Suppl 2): S61-S65.
61. Naisbitt DJ, Depta J, Wong G, et al. Anticonvulsant hypersensitivity syndrome: methodology to investigate the role of metabolism and processing of carbamazepine to T-cells. Br J Clin Pharmacol 2002; 53: 443P-443P.
62. Naisbitt DJ, Britschgi M, Wong G, et al. Anticonvulsant hypersensitivity syndrome: characterization of the phenotype and cytokine profile o carabamazepine-specific T-cell clones. Br J Clin Pharmacol 2002; 53: 418P-419P.
63. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DP,and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 2002; 359: 727-732.
64. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-1122.